2-bromo-2’5’-dihydroxychalcone analogue Inhibits Endothelial Migration by Targeting VEGF-induced ERK 1/2 Phosphorylation

Author:

Hussain Aamir,Festa Joseph,Singh Harprit

Abstract

AbstractAngiogenesis, the process of new blood vessel formation, is characterized by three essential hallmarks: endothelial proliferation, migration, and differentiation. Each is integral in angiogenesis related diseases, especially cancer. With drug efficacy stagnated due to acquired drug resistance and off target side effects, the need for combinatorial therapy is ever more present. To identify new compounds that could aid current antiangiogenic therapies, we report the preliminary mechanistic evaluation of a 2-bromo-2’5’-dihydroxychalcone analogue and its antimigratory effects on endothelial cells. After the synthesis and validation of the 2-bromo-2’5’-dihydroxychalcone analogue (AH9), its effect was tested in vitro using human umbilical vein endothelial cells (HUVEC). Initial investigations into 2-bromo-2’5’-dihydroxychalcone effect in vitro was conducted with a cell proliferation assay including MTT, afterward endothelial migration was measured with the scratch assay in subsequent functional studies. For mechanistic evaluation, vascular endothelial growth factor (VEGF) induced ERK phosphorylation using western blot was implemented. AH9 inhibited VEGF-induced ERK ½ phosphorylation similar to that of known antiangiogenic drug Sorafenib at all three concentrations 100 μM (46%,p= 0.003), 30 μM (64%,p= 0.0002) and 10 μM (91%,p= 0.0001). In a scratch assay model, whilst sorafenib at 3 μM was not able to limit migration after 8-hr compared to an untreated control (p = 0.0978), AH9 did (17.41%, p = 0.0079). Furthermore, AH9 was able to inhibit ERK ½ phosphorylation in a concentration dependent manner 100 μM (46%, p = 0.003), 30 μM (64%, p = 0.0002) and 10 μM (91%, p = 0.0001) compared to the VEGF control. These preliminary findings support that AH9 could be exerting antimigratory effects through the inhibition of the VEGF induced MAPK/ERK pathway. This forms the foundation for further studies to explore chalcone analogues in hope to aid current antiangiogenic therapeutic strategies as potential angiogenic inhibitors.

Publisher

Cold Spring Harbor Laboratory

Reference47 articles.

1. Antiangiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies – A review;Journal of Advanced Research,2017

2. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NFkappaB and Akt as targets;The FASEB journal : official publication of the Federation of American Societies for Experimental Biology,2006

3. Modes of resistance to anti-angiogenic therapy, Nature reviews;Cancer,2008

4. Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiinflammatory and anticancer chemopreventive activity;International journal of tissue reactions,1999

5. New natural products as new leads for antibacterial drug discovery;Bioorganic & medicinal chemistry letters,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3